Lenalidomide Formulation with Controlled Particle Size
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical formulations of Lenalidomide lack data on solubility and dissolution characteristics, making it challenging to develop generic versions that are bioequivalent to branded products like REVLIMID®, and there is a need for flexible formulation processes that can accommodate various modifications of Lenalidomide.
Innovation Solution
Development of pharmaceutical compositions comprising Lenalidomide base, salt, or cocrystal forms, with specific particle size distributions and combinations with pharmaceutically acceptable excipients, using a dry-powder-blending process to ensure consistent dissolution profiles across different media, mimicking the branded product REVLIMID®.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If different Lenalidomide modifications (polymorphs, salts, cocrystals, solvates) are used in pharmaceutical formulations, then formulation flexibility and adaptability are improved, but prediction of dissolution behavior and bioequivalence becomes more difficult
Solution Approach 1:
The patent systematically varies formulation parameters including particle size distribution (d10, d50, d90 values), excipient ratios, and processing conditions to establish their impact on dissolution profiles. This allows prediction of dissolution behavior across different Lenalidomide modifications by adjusting these parameters accordingly.
Solution Approach 2:
The patent performs preliminary characterization of Lenalidomide modifications including XRD, DSC, and dissolution testing before formulation development. This preliminary data establishes baseline properties that guide subsequent formulation design and bioequivalence assessment, enabling more reliable predictions.
2Adaptability or versatility
If Lenalidomide is formulated with various excipients using traditional methods, then manufacturing options are increased, but dissolution profile consistency and bioequivalence achievement become unpredictable
Solution Approach 1:
The patent employs dynamic optimization where formulation parameters are adjusted based on measured dissolution profiles. Particle size distributions and excipient ratios are fine-tuned iteratively to achieve target dissolution profiles, allowing adaptation while maintaining consistency through controlled feedback loops.
Solution Approach 2:
The patent develops a universal formulation platform that can accommodate different Lenalidomide modifications (base form, salts, cocrystals, solvates) using the same core excipient system and processing method. This multi-functional approach ensures dissolution consistency across various API forms while maintaining manufacturing flexibility.
3Reliability
If particle size reduction is applied to improve dissolution rate, then bioavailability is enhanced, but manufacturing complexity and process control difficulty increase
Solution Approach 1:
The patent applies partial particle size reduction targeting specific particle size ranges (d10, d50, d90 specifications) rather than complete micronization. This partial action achieves sufficient dissolution enhancement while avoiding the excessive complexity of full nanoscale processing, maintaining manufacturability.
Solution Approach 2:
The patent uses excipients as intermediaries that facilitate dissolution without requiring extreme particle size reduction. The excipient matrix acts as a mediator that enhances drug release through solubilization and disintegration mechanisms, reducing the need for complex size reduction equipment and process control.
Data Source
AI summary
The present invention relates to pharmaceutical compositions comprising the active substance Lenalidomide in one of the modifications selected from Lenalidomide base, a Lenalidomide salt, a Lenalidomide cocrystal or mixtures thereof, wherein the Lenalidomide particles have a particle size distribution (d90) ranging from 1 μm to 100 μm.